Navigation Links
Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
Date:9/23/2014

Eureka Therapeutics, Inc. announced today that the Company has secured $21 million in a Series C Financing. The new funding will be used to expand the Company's cancer immunotherapy pipeline and advance its lead programs to clinical development. New investor Yuan Capital led the round, with participation from Majuven and all existing major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital.

Eureka is engaged in the discovery and development of fully-human antibodies engineered to mimic the functions of a T cell receptor, a key component of the immune system. These therapeutic antibodies are designed to recognize proteins residing inside of cancer cells, and mobilize a patient's immune system to recognize and kill the diseased cell.

"This new funding will allow us to expand and advance our drug pipeline, as well as explore the synergistic effects of our drug candidates with other immunotherapies and immune modulators," said Cheng Liu, PhD, President and CEO of Eureka Therapeutics. "This moves us closer to our goal of providing cancer patients with safer and more effective treatments through novel immunotherapies."

"We are pleased to have the continued confidence and support of our existing investors, and we welcome our new investors," added Dr. Liu.

Earlier this year, the Company announced a license agreement with Novartis for the development and commercialization of ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers. The antibody, targeting the intracellular protein WT1, was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.


'/>"/>

Contact: Elisa Pan
admin@eurekainc.com
510-654-7045
Eureka Therapeutics, Inc.

Source:Eurekalert

Page: 1

Related biology news :

1. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
2. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
3. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
4. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
5. Industry group release testing recommendations for oligonucleotide-based therapeutics
6. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
9. Emerging class of therapeutics represents a coming wave for developers and manufacturers
10. Natura Therapeutics product shown to improve decision making skills in older adults
11. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2018)... FREMONT, Calif. (PRWEB) , ... December 04, 2018 ... ... their latest high throughput oligo synthesizer, the Dr. Oligo 192c, built on Biolytic’s ... key design aspects that have allowed them to become the world’s fastest in ...
(Date:11/27/2018)... ... November 27, 2018 , ... Earthres Group, Inc., a ... Operating Officer (COO). Dave joins the executive leadership team at EARTHRES in ... Dave will also serve in a key strategic role by helping drive ...
(Date:11/27/2018)... , ... November 27, 2018 , ... ... The companies have worked together to integrate the LabArchives Classroom Edition with Current ... combined offering will be available beginning January of 2019. , The ...
Breaking Biology News(10 mins):
(Date:12/5/2018)... ... December 05, 2018 , ... The incredible life story of ... in the European Parliament by Carlos Moedas, the European Commissioner for Research and Innovation. ... Innovation in Our Daily Lives, Commissioner Moedas spoke at length of Yousef’s life and ...
(Date:11/29/2018)... , ... November 29, 2018 , ... RAGS, today announced ... by Kickstart Seed Fund, with participation from existing investor and board member Jeremy Andrus, ... Smith of Cotopaxi. The additional funding will enable the company to accelerate its growth ...
(Date:11/26/2018)... ... November 26, 2018 , ... ... Siemens Healthineers and Omphalos Venture Partners (Virtual Radiologic founders) among other healthcare investors ... Nov. 25-29 at McCormick Place in Chicago. The company is proud to announce ...
(Date:11/20/2018)... (PRWEB) , ... November 20, 2018 , ... Each year ... 30 Under 30 list which highlights outstanding performance by individuals under 30 years of ... wide range of fields from Sports and Entertainment to Venture Capital and Science. ...
Breaking Biology Technology: